HOME >> MEDICINE >> NEWS
Costs of medical institutional review boards' greater than previously estimated

Institutional review boards (IRBs), the committees that oversee protections for human research participants, often come with a higher than expected price tag, according to results of a study published in the April 28 edition of the New England Journal of Medicine.

Researchers, led by Jeremy Sugarman, M.D., M. P. H., professor of bioethics and medicine at the Hopkins Berman Bioethics Institute, examined data from 63 academic medical centers in the United States to assess the costs for running their IRBs. They found that the annual operating costs ranged from $171,014 to $4,705,333, with a median cost of $741,920.

"Previous reports tended to understate the true costs of IRBs," says Sugarman. "Our study demonstrates that institutions and policy makers need to recognize the important role of the IRBs in protecting research participants so that they are not shortchanged."

To derive the full costs, the researchers calculated costs of salaries of IRB members, time spent on various IRB-related activities, the costs of office space, equipment, supplies and travel, and the use of outside services to facilitate and complement the work of the IRB. Low-volume institutions (fewer than 350 new research protocols reviewed by an IRB per year) had on average six IRB staff members, and high-volume centers (700 or more new protocols per year) had 14. The mean number of IRB panels in low-volume institutions was 1.8 and in high-volume institutions, 4.1.

Low-volume institutions had the lowest IRB costs (mean $402,369). Intermediate-volume centers had a mean cost of $805,620, while high-volume institutions had the highest mean cost of $1,150.417 per year.

High-volume medical centers, while spending more for IRBs in total, did benefit from an economy of scale, Sugarman said. At these institutions, each IRB review averaged $431 versus $644 for their low-volume counterparts. Intermediate-volume centers' cost per IRB review was $612.


'"/>

Contact: Gary Stephenson
gstephenson1@jhmi.edu
410-955-5384
Johns Hopkins Medical Institutions
27-Apr-2005


Page: 1

Related medicine news :

1. Costs of treating arthritis on the rise nationwide, study finds
2. Costs of long-course palliative radiotherapy acceptable in late-stage lung cancer
3. Conference Costs/Benefits of HIV/AIDS Interventions Developing Countries
4. Costs of polypill could drain global health budgets
5. Costs of coronary artery bypass graft surgery
6. Test project of patient-centered medical home model endorsed by American College of Physicians
7. Heroes of Chemistry honored for medical, energy, environmental breakthroughs
8. Refusal of medical and surgical interventions common among chronically ill elderly
9. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
10. When minority patients have insurance and a medical home, their health care improves
11. Extended duration work shifts risky to the safety, well-being of medical interns, patients

Post Your Comments:
(Date:5/21/2013)... DISCcert has served the training industry ... 17 DISC applications at the July 25 & 26th ... The July 25 & 26th DISC certification in San ... applying DISC. The time-tested, proven support materials will include ... DISC training materials ; worksheets, handouts, learning activities, ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... to protecting the rights of victims injured by defective ... Journal of Bone & Joint Surgery on May 15, ... can be used to identify complications that occur in ... any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...
(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...
(Date:5/21/2013)... OR (PRWEB) May 21, 2013 Phoseon ... systems at the 20th Annual IMI European Ink ... a proven market leader, Phoseon continues to invest in ... accelerating the adoption of UV LED curing in printing ... product families on the market offering both air cooled ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2
(Date:5/21/2013)... Md. , May 21, 2013 ... disposable drug-free consumer electronic devices, announced that CEO, ... presenting today to the FDA,s Medical Advisory Committee, ... the company,s products for over the counter sales. ... FDA developed its medical device classification schema," Whelan ...
(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue:   ... Optical Coherence Tomography (OCT) ... OBJECTIVES   BCC,s ... offer synopsis of the current and future ...
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 /PRNewswire/ ... Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ... positive Phase 2a study results of dupilumab (SAR231893/REGN668) in ... monoclonal antibody targeting the alpha subunit of the interleukin ... IL-4 and IL-13, drivers of Th2 (Type 2 helper ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7
Cached News: